The University of Southampton
University of Southampton Institutional Repository

Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD

Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD
Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD

Background and aims: Some previous studies reported serum autoantibody positivity in patients with nonalcoholic fatty liver disease (NAFLD). The clinical significance of these findings remains uncertain. We aimed to investigate the association between the presence of serum autoantibodies and liver disease severity in NAFLD. Methods and results: A total of 388 consecutive patients with biopsy-proven NAFLD were included in the study. Various serum autoantibodies (including also anti-nuclear antibodies [ANA]) were detected by indirect immunofluorescent or immunoblotting assays. Overall, 84 (21.6%) patients with biopsy-confirmed NAFLD had positivity for at least one of the measured serum autoantibodies. ANA positivity was present in 50 (12.9%) patients, whereas anti-U1RNP or pANCA antibodies were detectable in 9 (2.3%) and 6 (1.5%) patients, respectively. Multivariate logistic regression analysis showed that ANA positivity (adjusted-odds ratio: 4.51, 95%CI: 1.77–11.5; P = 0.002) or positivity of any serum autoantibodies (adjusted-odds ratio: 3.14, 95%CI: 1.30–7.62; P = 0.01) were independently associated with advanced liver fibrosis (stages F3–F4). In serum autoantibody/ANA-positive patients, the proportion of those with advanced fibrosis was also greater among carriers of PNPLA3 rs738409 GG or CG than among those carrying PNPLA3 rs738409 CC genotype. Conclusions: Serum autoantibody positivity was independently associated with advanced liver fibrosis in patients with biopsy-proven NAFLD. The presence of serum autoantibodies in patients with advanced fibrosis occurred more frequently amongst those carrying PNPLA3 rs738409 GG or CG genotypes.

Autoantibodies, Fibrosis, Liver biopsy, NAFLD
0939-4753
552-560
Zhou, Yu-Jie
d1b49b9c-d589-4814-8e13-c81e62a05c9e
Zheng, Kenneth I.
54347301-6824-423a-a534-f29cfc06e536
Ma, Hong-Lei
197d9905-121a-4035-b3b1-3d9dbec9e39a
Li, Gang
30fd7abe-28e0-4828-84fe-0144cc9dbc5d
Pan, Xiao-Yan
b8463cc6-3ae1-4f9f-9ec1-3b4b3722580d
Zhu, Pei-Wu
2dd2649f-9c65-4568-9116-5d2246070a9e
Targher, Giovanni
043e0811-b389-4922-974e-22e650212c5f
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Wang, Xiao-Dong
631d817b-c8ce-4398-941d-5d88cc2b2bde
Chen, Yong-Ping
55955857-91b3-4845-97fc-fff4091190a9
Li, Xiao-Bo
94a7852c-dd60-44d5-a835-3365f8b446a6
Zheng, Ming-Hua
eca8d15a-692d-4114-a518-fc8fdac34331
Zhou, Yu-Jie
d1b49b9c-d589-4814-8e13-c81e62a05c9e
Zheng, Kenneth I.
54347301-6824-423a-a534-f29cfc06e536
Ma, Hong-Lei
197d9905-121a-4035-b3b1-3d9dbec9e39a
Li, Gang
30fd7abe-28e0-4828-84fe-0144cc9dbc5d
Pan, Xiao-Yan
b8463cc6-3ae1-4f9f-9ec1-3b4b3722580d
Zhu, Pei-Wu
2dd2649f-9c65-4568-9116-5d2246070a9e
Targher, Giovanni
043e0811-b389-4922-974e-22e650212c5f
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Wang, Xiao-Dong
631d817b-c8ce-4398-941d-5d88cc2b2bde
Chen, Yong-Ping
55955857-91b3-4845-97fc-fff4091190a9
Li, Xiao-Bo
94a7852c-dd60-44d5-a835-3365f8b446a6
Zheng, Ming-Hua
eca8d15a-692d-4114-a518-fc8fdac34331

Zhou, Yu-Jie, Zheng, Kenneth I., Ma, Hong-Lei, Li, Gang, Pan, Xiao-Yan, Zhu, Pei-Wu, Targher, Giovanni, Byrne, Christopher, Wang, Xiao-Dong, Chen, Yong-Ping, Li, Xiao-Bo and Zheng, Ming-Hua (2021) Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. Nutrition, Metabolism & Cardiovascular Diseases, 31 (2), 552-560. (doi:10.1016/j.numecd.2020.10.004).

Record type: Article

Abstract

Background and aims: Some previous studies reported serum autoantibody positivity in patients with nonalcoholic fatty liver disease (NAFLD). The clinical significance of these findings remains uncertain. We aimed to investigate the association between the presence of serum autoantibodies and liver disease severity in NAFLD. Methods and results: A total of 388 consecutive patients with biopsy-proven NAFLD were included in the study. Various serum autoantibodies (including also anti-nuclear antibodies [ANA]) were detected by indirect immunofluorescent or immunoblotting assays. Overall, 84 (21.6%) patients with biopsy-confirmed NAFLD had positivity for at least one of the measured serum autoantibodies. ANA positivity was present in 50 (12.9%) patients, whereas anti-U1RNP or pANCA antibodies were detectable in 9 (2.3%) and 6 (1.5%) patients, respectively. Multivariate logistic regression analysis showed that ANA positivity (adjusted-odds ratio: 4.51, 95%CI: 1.77–11.5; P = 0.002) or positivity of any serum autoantibodies (adjusted-odds ratio: 3.14, 95%CI: 1.30–7.62; P = 0.01) were independently associated with advanced liver fibrosis (stages F3–F4). In serum autoantibody/ANA-positive patients, the proportion of those with advanced fibrosis was also greater among carriers of PNPLA3 rs738409 GG or CG than among those carrying PNPLA3 rs738409 CC genotype. Conclusions: Serum autoantibody positivity was independently associated with advanced liver fibrosis in patients with biopsy-proven NAFLD. The presence of serum autoantibodies in patients with advanced fibrosis occurred more frequently amongst those carrying PNPLA3 rs738409 GG or CG genotypes.

Text
draft-R2_final - Accepted Manuscript
Download (111kB)
Image
Figure 1 - Accepted Manuscript
Download (184kB)
Image
Figure 2 - Accepted Manuscript
Download (146kB)
Text
Supplementary Table 1 - Accepted Manuscript
Download (18kB)
Text
Supplementary Table 2 - Accepted Manuscript
Download (18kB)
Text
Table 1 - Accepted Manuscript
Download (29kB)
Text
Table 2 - Accepted Manuscript
Download (18kB)
Text
Table 3 - Accepted Manuscript
Download (20kB)
Text
Table 4 - Accepted Manuscript
Download (19kB)

Show all 9 downloads.

More information

Accepted/In Press date: 6 October 2020
e-pub ahead of print date: 13 October 2020
Published date: 8 February 2021
Keywords: Autoantibodies, Fibrosis, Liver biopsy, NAFLD

Identifiers

Local EPrints ID: 444566
URI: http://eprints.soton.ac.uk/id/eprint/444566
ISSN: 0939-4753
PURE UUID: c11afd0b-84f3-42e7-aead-3f0118e143ab
ORCID for Christopher Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 26 Oct 2020 17:31
Last modified: 17 Mar 2024 05:59

Export record

Altmetrics

Contributors

Author: Yu-Jie Zhou
Author: Kenneth I. Zheng
Author: Hong-Lei Ma
Author: Gang Li
Author: Xiao-Yan Pan
Author: Pei-Wu Zhu
Author: Giovanni Targher
Author: Xiao-Dong Wang
Author: Yong-Ping Chen
Author: Xiao-Bo Li
Author: Ming-Hua Zheng

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×